10-Q: Recursion Pharmaceuticals Reports Q3 2024 Results, Highlights Clinical Progress and Strategic Collaborations

Recursion Pharmaceuticals announced its Q3 2024 financial results, showcasing increased revenue and advancements in its clinical programs and strategic partnerships.

Summary

• Recursion Pharmaceuticals reported a net loss of $95.8 million for the third quarter of 2024, compared to a net loss of $93.0 million for the same period in 2023.
• The company's operating revenue increased significantly to $26.1 million in Q3 2024, up from $10.1 million in Q3 2023, primarily due to its collaboration with Roche.
• Research and development expenses totaled $74.6 million for the quarter, a slight increase from $70.0 million in the prior year.
• General and administrative expenses also rose to $37.8 million, compared to $29.2 million in the same quarter of the previous year.
• For the nine months ended September 30, 2024, the company's net loss was $284.8 million, compared to $235.1 million for the same period in 2023.
• The company's cash and cash equivalents stood at $427.6 million as of September 30, 2024.
• Recursion believes its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months.
• The company is advancing multiple clinical programs, including REC-994 for Cerebral Cavernous Malformation, REC-2282 for Neurofibromatosis Type 2, and REC-4881 for Familial Adenomatous Polyposis.
• A $30 million milestone payment was received from Roche related to the first accepted neuroscience Phenomap.
• The company has an agreement to acquire Exscientia plc, which is subject to shareholder and regulatory approvals.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The company shows strong revenue growth and clinical progress, but also significant losses and the need for future capital raises. The overall sentiment is cautiously optimistic, reflecting the potential of the company's technology and pipeline, balanced with the inherent risks of drug development.

Positives

• Significant increase in operating revenue driven by strategic partnerships.
• Positive results from the Phase 2 trial of REC-994, indicating potential for further development.
• Advancement of multiple clinical programs into Phase 2 trials.
• Successful public offering of Class A common stock, strengthening the company's financial position.
• Strategic collaborations with Roche and Google Cloud, enhancing research and development capabilities.
• The company has a strong cash position of $427.6 million.

Negatives

• The company continues to incur significant operating losses, with a net loss of $95.8 million in Q3 2024.
• Research and development expenses remain high, totaling $74.6 million for the quarter.
• General and administrative expenses have increased to $37.8 million.
• The company has an accumulated deficit of $1.3 billion.

Risks

• The company is subject to the risks and uncertainties of clinical trial outcomes.
• The company will require additional capital to advance its drug candidates.
• The company's ability to access capital when needed is not assured.
• The company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry.
• The company is subject to the risk of intellectual property disputes.
• The company is subject to the risk of cybersecurity breaches.
• The company is subject to the risk of delays in clinical trials.
• The company is subject to the risk of not being able to obtain favorable terms of collaboration, licensing, or other arrangements.
• The company is subject to the risk of not being able to maintain its technical operations infrastructure.
• The company is subject to the risk of not being able to attract and retain personnel.
• The company is subject to the risk of ownership changes that may limit the amount of net operating losses and tax credit carryforwards that can be utilized annually to offset future taxable income.

Future Outlook

Recursion believes its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months. The company anticipates needing to raise additional financing in the future to fund operations, including the potential commercialization of any approved product candidates.

Management Comments

• Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery.
• We believe Recursions unbiased, data-driven approach to understanding biology will bring more, new and better medicines at higher scale and lower cost to patients.
• We drive value by scaling and leveraging the Recursion OS to generate, aggregate and integrate over 50 petabytes of data.
• With our approach and our team of over 500 Recursionauts that is balanced between life scientists and computational and technical experts, we endeavor to turn drug discovery into a search problem.

Industry Context

The announcement reflects the ongoing trend of integrating technology and data analytics into drug discovery, with Recursion leveraging its proprietary platform and AI/ML capabilities. The company's strategic partnerships and clinical advancements position it as a key player in the TechBio sector, competing with other companies that are also using data-driven approaches to accelerate drug development.

Comparison to Industry Standards

• Recursion's revenue growth, driven by its Roche collaboration, is notable compared to other early-stage biotech companies that often rely solely on funding rounds.
• The company's focus on AI and machine learning in drug discovery aligns with industry trends, but its proprietary platform and data universe differentiate it from competitors.
• The clinical trial results for REC-994 are promising and could position Recursion favorably against companies developing treatments for similar conditions.
• The acquisition of Exscientia is a significant move, potentially creating a larger and more competitive entity in the TechBio space, similar to other mergers and acquisitions seen in the industry.
• The company's cash position is relatively strong compared to other companies of similar size, providing a runway for continued development.

Legal Proceedings

• The company is involved in a legal proceeding with Industry Office SLC, LLC related to a lease agreement.

Stakeholder Impact

• Shareholders may experience dilution from future capital raises.
• Employees are impacted by the company's financial performance and strategic direction.
• Customers and partners are impacted by the company's research and development progress.
• Creditors are impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• The company plans to meet with the FDA and advance the development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies.
• The company plans to present the Phase 2 data for REC-994 at a medical conference and publish results in a peer reviewed scientific journal.
• The company expects to share an update on the Phase 2/3 POPLAR clinical trial for REC-2282 in Q4 2024.
• The company expects to share Phase 2 safety and preliminary efficacy data for REC-4881 in H1 2025.
• The company expects a preliminary readout from the Phase 2 ALDER clinical trial for REC-3964 by the end of 2025.
• The company plans to initiate dosing of Phase 1/2 for REC-1245 in Q4 2024.
• The company expects Phase 1 data from the dose-escalation portion of the study for REC-1245 by the end of 2025.
• The company expects an IND submission for its lead candidate in fibrosis in early 2025.
• The company will continue to advance efforts to discover potential new therapeutics with its strategic partners.
• The company will continue to explore generative AI capabilities with Google Cloud.
• The company will seek shareholder and regulatory approvals for the acquisition of Exscientia.

Key Dates

Keywords

drug discovery, clinical trials, biotechnology, pharmaceuticals, precision oncology, rare diseases, artificial intelligence, machine learning, strategic partnerships, genetics, phenomaps, RBM39 degrader, Cerebral Cavernous Malformation, Neurofibromatosis Type 2, Familial Adenomatous Polyposis, Clostridioides difficile infection